Bristol Myers Bags RayzeBio in $4.1B Cancer Fight Pact

Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion to Expand Presence in Oncology Sector

**Bristol Myers Squibb** is making a big move in the oncology sector with its acquisition of **RayzeBio** for a whopping $4.1 billion. This strategic move highlights the pharma giant’s ambitions to grow its presence in the cancer therapeutics field. The deal comes after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act on February 9, 2024.